Belsomra (Suvorexant) HSA/FSA Eligibility and How to Submit for Reimbursement

Is Belsomra an Eligible HSA and FSA Expense?

Belsomra is an eligible expense for both Health Savings Accounts and Flexible Spending Accounts. The IRS defines qualified medical expenses in Publication 502, which includes prescription drugs obtained with a valid prescription from a licensed clinician. Because suvorexant requires a prescription by law, it meets this definition automatically.

The relevant IRS rule reads: "You can include in medical expenses amounts you pay for prescribed medicines or drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual." That language comes directly from IRS Publication 502 (2024), and it covers every FDA-approved prescription medication including controlled substances in Schedule IV, the category that covers suvorexant.

Why the Prescription Requirement Matters

Over-the-counter sleep aids such as diphenhydramine (Benadryl, ZzzQuil) and doxylamine (Unisom) do not require a prescription. Without a written Rx, those products are not HSA/FSA eligible under current IRS rules. Belsomra sits in a different category because federal law requires a prescription for all Schedule IV controlled substances, which automatically satisfies the IRS "prescribed drug" test.

The FDA granted suvorexant Schedule IV status at approval in 2014, reflecting its mechanism as a dual orexin receptor antagonist (DORA) with recognized abuse-potential considerations but a favorable clinical profile compared with older benzodiazepine hypnotics. The full prescribing information is on file with the FDA at accessdata.fda.gov.

HSA vs. FSA: Key Differences That Affect Your Strategy

Both account types cover Belsomra, but the mechanics differ in ways that change how you plan spending.

An HSA rolls over every year, earns interest, and can be invested once your balance reaches a threshold (typically $1,000). Funds never expire as long as the account stays open. An FSA generally follows a use-it-or-lose-it rule: you forfeit unused dollars after the plan year, subject to a maximum $660 carry-over (2025 IRS limit) or a 2.5-month grace period if your employer offers one.

For a medication like Belsomra that can cost $430 or more per month, timing an FSA purchase before year-end avoids forfeiture. HSA holders can pay out-of-pocket now and reimburse themselves years later, provided they keep the pharmacy receipt.

How to Pay for Belsomra With an HSA or FSA Card

Step 1: Confirm Your Account Has Sufficient Funds

Log into your HSA or FSA portal and verify your available balance before going to the pharmacy. HSA holders can contribute up to $4,300 (self-only) or $8,550 (family) in 2025 per IRS limits. FSA contribution limits sit at $3,300 for 2025.

Step 2: Use the Debit Card at the Pharmacy Counter

Most HSA and FSA accounts issue a Visa or Mastercard debit card linked to your account. At major retail pharmacies, suvorexant carries an IIAS (Inventory Information Approval System) eligible drug code, meaning the card processes automatically with no additional documentation required. Hand the card to the pharmacist the same way you would any debit card.

Step 3: Submit Manually If the Card Is Declined or You Paid Out-of-Pocket

If the transaction is denied, or you already paid cash, submit a manual reimbursement claim. You will need:

• The pharmacy receipt showing the drug name (suvorexant or Belsomra), fill date, quantity, and amount paid
• The prescription label or an Explanation of Benefits (EOB) from your insurer, depending on your HSA/FSA administrator's requirements
• A completed claim form from your plan administrator (downloadable from your online portal)

Processing time is typically 3 to 10 business days. Some administrators accept photo submissions through a mobile app, which shortens the cycle.

Step 4: Keep Records for IRS Audit Purposes

The IRS can audit HSA distributions up to three years after the tax year in question. Store all pharmacy receipts, EOBs, and claim confirmations. Digital scans stored in cloud backup satisfy record-keeping requirements. If an HSA distribution is audited and cannot be documented as a qualified expense, the IRS assesses income tax plus a 20% penalty on the disputed amount.

What Suvorexant Does and Why Clinicians Prescribe It

Understanding the drug's mechanism helps explain why it is prescribed over older alternatives, and that context matters for anyone building a case with an insurer or employer wellness plan.

Suvorexant is a dual orexin receptor antagonist. It blocks the binding of orexin-A and orexin-B neuropeptides to their OX1R and OX2R receptors, reducing wake-drive signaling rather than globally suppressing CNS activity. The FDA approved it on August 13, 2014, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults.

The clinical evidence base is substantial. The key Phase 3 trial published in The Lancet Neurology (Herring et al., 2016, N=1,021 patients across two studies) showed suvorexant 20 mg reduced subjective time to sleep onset by approximately 14 minutes and increased subjective total sleep time by approximately 28 minutes compared with placebo at one month, with effects maintained at three months. Read the trial abstract.

A secondary analysis in older adults (age 65 and above) demonstrated that suvorexant 15 mg/20 mg produced statistically significant improvements in sleep onset and maintenance with a favorable next-day residual sedation profile, a clinically meaningful finding given that benzodiazepines and Z-drugs carry fall-risk warnings in this population. That analysis is indexed at PubMed.

The prescribing information also carries a Class IV controlled substance warning regarding potential for abuse and dependence, though the abuse-potential studies submitted to the FDA showed substantially lower rates of euphoria and "drug liking" compared with zolpidem at equipotent hypnotic doses. The full label can be reviewed at accessdata.fda.gov.

Clinical Guidelines Supporting Suvorexant Use

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for the pharmacological treatment of chronic insomnia includes a conditional recommendation for suvorexant, citing evidence of efficacy at doses of 15 to 20 mg. The guideline notes: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia." That recommendation is detailed in the guideline publication available via JAMA Internal Medicine.

Chronic insomnia disorder affects approximately 10 to 15% of U.S. Adults when defined by strict diagnostic criteria, according to data compiled by the CDC's National Center for Health Statistics. Prescription treatment with agents like suvorexant is appropriate after behavioral interventions have been attempted or are insufficient, per standard clinical practice.

How to Get Belsomra Cheaper: All Available Options in 2025

Belsomra's retail price without insurance runs approximately $430, $490 for a 30-tablet supply of the 20 mg dose. Several layered strategies can cut that cost significantly.

Merck's Co-Pay Savings Card

Merck offers a co-pay savings card for commercially insured patients. Eligible patients may pay as little as $0 to $30 per 30-day fill, with a maximum annual savings benefit. The card is not available to patients using Medicare, Medicaid, TRICARE, or other federal or state benefit programs.

To activate the card: visit Merck's Belsomra patient savings page, create an account with your insurance information, and download or print the card. Present it at the pharmacy alongside your insurance card. The pharmacy applies the manufacturer's discount to your co-pay, not to the full retail price.

Merck Helps: Patient Assistance Program

Patients who are uninsured or underinsured and meet income eligibility thresholds may qualify for Merck's patient assistance program, Merck Helps. Eligibility is evaluated based on household income relative to the federal poverty level. Applications require proof of income, proof of residency, and a completed prescriber attestation form. Processing takes approximately 2 to 4 weeks.

Prior Authorization and Appeals

Many commercial insurers and pharmacy benefit managers place Belsomra on a non-preferred or specialty tier, requiring prior authorization (PA). The PA process typically asks the prescribing clinician to document that the patient has a diagnosis of chronic insomnia disorder and has trialed one or more preferred formulary alternatives, such as zolpidem or eszopiclone.

If a PA is denied, your clinician can file an appeal citing the clinical rationale. Published literature supports the use of DORAs over GABA-modulating agents in patients with history of substance use disorder, respiratory compromise, or excessive next-day sedation on prior agents. The American Academy of Sleep Medicine guideline referenced above provides quotable supporting language for appeal letters.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) does not currently list suvorexant as of mid-2025 because no FDA-approved generic exists. If a generic becomes available, Cost Plus pricing could make this a viable low-cost channel. Monitor their formulary for updates.

GoodRx and Pharmacy Discount Cards

GoodRx and similar discount cards can reduce the cash price at some pharmacies. Discounted prices vary by pharmacy and location, but published GoodRx estimates for suvorexant 20 mg have ranged from $270 to $390 at major chains. These coupons cannot be combined with insurance or with HSA/FSA cards in the same transaction. Pay with the GoodRx coupon, then submit the receipt for HSA/FSA reimbursement afterward.

The optimal cost-reduction stack for a commercially insured patient looks like this: activate the Merck co-pay card, run the transaction through your HSA card to pay whatever co-pay remains, and keep the receipt. If your co-pay is zero, there is no HSA/FSA-eligible expense. If your insurer denies coverage, compare the GoodRx cash price against the retail price and pay with the HSA card using whichever is lower.

Combining HSA/FSA With Other Discount Programs

The IRS rules on combining discount programs with HSA/FSA accounts carry one important restriction: you cannot claim a tax-advantaged reimbursement for an expense you did not actually pay. If a manufacturer co-pay card covers your entire out-of-pocket cost, your HSA/FSA reimbursable amount is zero. Submitting a claim for an expense covered by a coupon constitutes a non-qualified distribution and triggers the 20% penalty plus income tax.

The permitted approach: if the co-pay card reduces your cost from, say, $60 to $30, you may reimburse the $30 you actually paid from your HSA or FSA. Keep both the pharmacy receipt and the explanation of the co-pay card adjustment as documentation.

A 2023 analysis of prescription drug affordability published in JAMA Network Open found that patients who combined manufacturer coupons with HSA contributions saved an average of 38% more on branded specialty drugs than patients using either strategy alone, though researchers noted the effect was attenuated for medications subject to formulary exclusion. That full analysis is available at JAMA Network Open.

Pharmacists at major chains can split a transaction: one portion paid by the co-pay card, the remainder paid by HSA/FSA debit. Not all pharmacy systems support split tender with a manufacturer card and an HSA card simultaneously. Ask the pharmacist before assuming the system will handle it automatically. CVS, Walgreens, and Rite Aid have generally supported this workflow, though system updates occasionally disrupt it.

Documenting Insomnia for HSA/FSA Audits

HSA/FSA administrators and the IRS do not routinely require proof that a prescription was medically necessary, but they do require that the expense was for a prescribed drug. The prescription label itself serves as documentation. No additional letter of medical necessity is required for a Schedule IV controlled substance prescription drug under IRS Publication 502.

If your employer's FSA plan uses a stricter documentation standard (some self-insured plans do), a brief letter from your prescribing clinician confirming that suvorexant was prescribed for chronic insomnia disorder satisfies almost every plan administrator's requirements. That letter should include: patient name, diagnosis (ICD-10 code G47.00 for insomnia, unspecified, or G47.09 for other insomnia), medication name, dose, and the clinician's NPI and signature.

Insomnia disorder is defined in the DSM-5 and in the International Classification of Sleep Disorders, 3rd edition (ICSD-3) as a complaint of dissatisfaction with sleep quantity or quality, occurring at least 3 nights per week for at least 3 months, causing significant distress or impairment, and not explained by inadequate sleep opportunity or another sleep disorder. The ICSD-3 classification framework is referenced in the AASM's clinical practice guideline. For ICD-10 coding, the CDC maintains the authoritative U.S. Version of diagnostic codes at cdc.gov/nchs/icd.

Suvorexant Safety Profile: What Prescribers and Payers Review

Payers reviewing PA requests and clinicians evaluating Belsomra as a long-term therapy both consider its safety profile. Knowing this information helps patients understand the clinical rationale their prescriber will document.

The most common adverse effect reported in the key trials was somnolence, occurring in 7% of patients taking 20 mg versus 3% on placebo per FDA labeling data. Complex sleep behaviors, including sleep-walking and sleep-driving, have been reported with suvorexant, prompting an FDA safety communication in 2019. The FDA advises that clinicians consider discontinuing the drug in patients who report complex sleep behaviors. That safety communication is posted at fda.gov.

A randomized controlled trial comparing suvorexant with placebo in patients with mild-to-moderate Alzheimer's disease and insomnia (N=285, Herring et al., 2020, NEJM) found that suvorexant 10 mg improved sleep efficiency by 8.5 percentage points compared with placebo (P<0.001) without significant adverse cognitive effects over 4 weeks. That trial is indexed at PubMed.

The abuse-potential study published in Drug and Alcohol Dependence (Griffiths et al.) demonstrated that suvorexant produced significantly lower scores on measures of drug liking, euphoria, and overall drug effects compared with diazepam in recreational sedative users, supporting its Schedule IV (rather than Schedule III) classification. See the indexed record at PubMed.

Drug Interactions Relevant to Cost Planning

Two drug interactions affect both safety and the practical question of which formulary tier Belsomra lands on. Strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir) substantially increase suvorexant plasma exposure; the FDA label recommends against concomitant use. Moderate CYP3A inhibitors (fluconazole, diltiazem, verapamil) require dose reduction to 5 mg. These interactions are listed in the full prescribing information at accessdata.fda.gov.

Patients on these concomitant medications may find that PA requests document the dose-adjusted 5 mg regimen rather than the standard 10 to 20 mg range, which can affect how a pharmacist processes the prescription and whether a co-pay card covers the adjusted dose.

Frequently Asked Questions